MedWatch

ALK CEO: Slow progress in the US has nothing to do with the allergy business

Danish allergy group ALK is still waiting for a real breakthrough in the US but it has nothing to do with the company's tablets or the allergy business, says the CEO, who instead points to postponed orders and calls ALK's entry to the US market a "long journey."

Foto: Niels Ahlmann Olesen / Ritzau Scanpix

"As far as I know, no other pharma company in Europe is growing faster than we do," states ALK CEO Carsten Hellmann.

With a total revenue growth of 9 percent in second quarter of 2019, things are looking promising for the Danish allergy group. Moreover, the company is in the middle of a large-scale transformation that is to elevate the annual sales growth to over 10 percent and ensure a revenue matching that of other pharma companies.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier